Volume 27, Number 1—January 2021
Research
Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes
Tony Wawina-Bokalanga, Bert Vanmechelen, Valentine Lhermitte, Joan Martí-Carreras, Valentijn Vergote, Fara Raymond Koundouno, Joseph Akoi-Boré, Ruth Thom, Tom Tipton, Kimberley Steeds, Kéita Balla Moussa, Ablam Amento, Lies Laenen, Sophie Duraffour, Martin Gabriel, Paula Ruibal, Yper Hall, Mandy Kader-Kondé, Stephan Günther, Guy Baele, Cesar Muñoz-Fontela, Johan Van Weyenbergh, Miles W. Carroll, and Piet Maes
Table 1
Frequency of KIR genes and HLA class I alleles among control group, Ebola survivors, and persons who died of Ebola virus disease, Guinea, 2015–2017*
| Gene | Controls, no. (%) | Survivors, no. (%) | Persons who died, no. (%) | p value |
|---|---|---|---|---|
| Inhibitory KIRs | ||||
| 2DL1 | 77 (100.0) | 101 (100.0) | 119 (100.0) | |
| 2DL2 | 67 (87.0) | 99 (98.0) | 99 (83.2) | †‡ |
| 2DL3 | 71 (92.2) | 94 (93.1) | 112 (94.1) | |
| 2DL4 | 77 (100.0) | 100 (99.0) | 118 (99.1) | |
| 2DL5 | 42 (54.5) | 47 (46.5) | 75 (63.0) | † |
| 3DL1 | 77 (100.0) | 101 (100.0) | 118 (99.1) | |
| 3DL2 | 76 (98.7) | 101 (100.0) | 119 (100.0) | |
| 3DL3 |
77 (100.0) |
101 (100.0) |
119 (100.0) |
|
| Activating KIRs | ||||
| 2DS1 | 46 (59.7) | 55 (54.4) | 74 (62.2) | |
| 2DS2 | 37 (48.0) | 46 (45.5) | 55 (46.2) | |
| 2DS3 | 23 (29.8) | 30 (29.7) | 40 (33.6) | |
| 2DS4–001 | 70 (90.9) | 94 (93.1) | 103 (86.6) | |
| 2DS4–003 | 40 (51.9) | 41 (40.6) | 67 (56.3) | † |
| 2DS5 | 23 (29.8) | 26 (25.7) | 40 (33.6) | |
| 3DS1 |
5 (6.5) |
4 (3.9) |
13 (10.9) |
|
| Pseudogenes | ||||
| 2DP1 | 77 (100.0) | 100 (99.0) | 116 (97.5) | |
| 3DP1–001 | 6 (7.8) | 4 (3.9) | 8 (6.7) | |
| 3DP1–004 |
76 (98.7) |
99 (98.0) |
117 (98.3) |
|
| HLA class I alleles | ||||
| HLA-C1Asn80 | 55 (71.4) | 78 (77.2) | 85 (71.4) | |
| HLA-C2Lys80 | 58 (75.3) | 74 (73.3) | 88 (73.9) | |
| HLA-B-Bw4Thr80 | 8 (10.4) | 9 (8.9) | 22 (18.5) | |
| HLA-B-Bw4Ile80 | 33 (42.8) | 48 (47.5) | 38 (31.9) | |
| HLA-A-Bw4 | 23 (29.8) | 26 (25.7) | 37 (31.1) |
*Frequency (%) of each KIR gene or HLA class I allele was calculated and defined as the number of individuals having the gene or allele divided by the number of persons in the studied group. HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; Pc, corrected p value. †p value <Pc (survivors vs. persons who died). ‡p value <Pc (controls vs. survivors).
Page created: October 16, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.